Duggan Michael R, Morgan David G, Price Brittani R, Rajbanshi Binita, Martin-Peña Alfonso, Tansey Malú Gámez, Walker Keenan A
Laboratory of Behavioral Neuroscience, National Institute on Aging, Intramural Research Program, Baltimore, MD, 21224, USA.
Department of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, MI, 49503, USA.
Mol Neurodegener. 2025 Mar 31;20(1):39. doi: 10.1186/s13024-025-00828-x.
Immune mechanisms play a fundamental role in Alzheimer's disease (AD) pathogenesis, suggesting that approaches which target immune cells and immunologically relevant molecules can offer therapeutic opportunities beyond the recently approved amyloid beta monoclonal therapies. In this review, we provide an overview of immunomodulatory therapeutics in development, including their preclinical evidence and clinical trial results. Along with detailing immune processes involved in AD pathogenesis and highlighting how these mechanisms can be therapeutically targeted to modify disease progression, we summarize knowledge gained from previous trials of immune-based interventions, and provide a series of recommendations for the development of future immunomodulatory therapeutics to treat AD.
免疫机制在阿尔茨海默病（AD）发病机制中起着基础性作用，这表明针对免疫细胞和免疫相关分子的方法可能提供超越近期获批的β淀粉样蛋白单克隆疗法的治疗机会。在本综述中，我们概述了正在研发的免疫调节疗法，包括它们的临床前证据和临床试验结果。除了详细阐述AD发病机制中涉及的免疫过程，并强调如何通过治疗靶向这些机制来改变疾病进程外，我们还总结了以往基于免疫干预试验所获得的知识，并为未来开发治疗AD的免疫调节疗法提供了一系列建议。
Zotero 插件